Last reviewed · How we verify
NCT04479280
Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.
trial testing Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA in Coagulation Disorder in 70 participants. Completed in 16 August 2020.
16 August 2020
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 20 July 2020 |
| Primary completion | 16 August 2020 |
| Estimated completion | 16 August 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA
Conditions studied
- Coagulation Disorder — all drugs for Coagulation Disorder →
Sponsor
Assiut University
Who can join
Eligibility, any sex, with Coagulation Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04479280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coagulation Disorder
Currently open trials in the same condition.
- NCT06481995 — SWIFT - SWIss Factor XIII Trial in PPH · Phase 4 · recruiting
- NCT05139589 — The ENDOCARDITIS AUMC Data Collection · recruiting
- NCT05156983 — A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery · Phase 3 · recruiting
- NCT05645081 — Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke · recruiting
- NCT04524637 — The Utility of Thromboelastography in Traumatic Brain Injury · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04479280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 9 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04479280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing